Discover how vasomotor symptoms and cardiometabolic risk can be addressed through effective hormone therapy solutions.

Abstract

As a clinician and researcher practicing integrative care in El Paso, I guide patients through menopause with a practical, physiology-first approach. In this educational post, I will explain the mechanisms behind vasomotor symptoms (VMS)—hot flashes and night sweats—using up-to-date research and a patient story to anchor the science. We will delve into the latest evidence-based findings on managing menopausal symptoms, exploring both hormonal and non-hormonal therapies, with a special focus on hormone replacement therapy (HRT), including transdermal, oral, and parenteral options. We break down the differences between estrogen-only and combination therapies, discuss the critical role of progestins for women with a uterus, and examine the benefits of SERMs. I describe how our multidisciplinary, integrative approach at Injury Medical Clinic PA combines integrative chiropractic care, targeted rehab, autonomic regulation, sleep optimization, and nutritional/functional medicine, all under medical oversight. Our team, led by me, Dr. Alex Jimenez, and Medical Director Dr. Maria Guadalupe Cardenas, MD, provides coordinated, evidence-based care for patients navigating menopause, personal injuries, and complex comorbidities, so you have the knowledge to make a healthier transition.

Introduction: Why Vasomotor Symptoms Deserve a Whole-Person Strategy

I meet many high-performing women who feel blindsided when hot flashes and night sweats hijack their routines, sleep, and confidence. Even professionals embedded in science and healthcare can miss the early signs because the transition is gradual, symptoms fluctuate, and conversations around menopause still lag behind the data. When a patient like Jenny, 52, tells me she is waking up drenched, “enveloped in a hot blanket,” and that these episodes have worsened over two years, my job is to connect her lived experience to the underlying physiology and build a treatment plan that is safe, individualized, and effective.

Our approach links:

• Clear definitions and staging of menopause using symptom timelines and menstrual patterns, not reflexive lab panels.
• Mechanistic insight into the hypothalamic set point, the narrowed thermoneutral zone, the role of KNDy neurons, and estrogen’s modulatory effects.
• Evidence-based therapies—hormonal and non-hormonal—selected by risk profile and symptom severity.
• Integrative chiropractic care that addresses autonomic balance, spinal-mechanical contributors to thermoregulation and sleep, and pain that amplifies VMS distress.
• Functional medicine tools: nutrition, micronutrients, cardiometabolic support, detoxification capacity, and inflammation control.
• Coordinated medical oversight by Internal Medicine to ensure safety, quality, and continuity, especially for women with comorbidities or those on hormone therapy.

Multidisciplinary Collaboration in El Paso: How Our Clinic Operates

At Injury Medical Clinic PA, we believe in a patient-centered, multidisciplinary approach to health and wellness. My name is Dr. Alex Jimenez, and my background spans chiropractic, functional medicine, and advanced practice nursing (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST). This diverse training allows me to view health through a holistic lens, focusing on the intricate connections within the body’s systems.

To provide the highest standard of comprehensive care, I am honored to collaborate with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is a highly respected, board-certified internal medicine physician with over four decades of experience. She serves as our Medical Director and Collaborative Physician at our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, bringing invaluable medical expertise and oversight. This model reflects a standard integrative and injury-care structure in which an MD provides medical direction, while chiropractic and rehab clinicians deliver conservative care aligned with medical best practices.

What this means for our patients:

• Medical Oversight (Dr. Cardenas): Cardenas provides medical diagnosis and prescription management (including hormone therapy) and ensures appropriate screening, differential diagnosis, and pharmacologic safety, including hormone therapy candidacy, cardiovascular risk stratification, and medication interactions.
• Integrative Chiropractic Management (Dr. Jimenez): I direct spinal and neuromusculoskeletal care that can influence autonomic tone, sleep quality, and pain—factors tightly linked to VMS intensity. I focus on musculoskeletal health, nervous system function, and structural alignment, which are crucial for overall well-being.
• Functional Medicine: We investigate the root causes of symptoms and use targeted nutrition, lifestyle changes, and advanced diagnostics to restore balance.
• Rehabilitation and Personal Injury Context: We offer specialized care for injuries, with a focus on restoring function and mobility. For patients whose symptoms are intensified by pain or trauma (e.g., whiplash, back strain), we integrate VMS management with injury recovery, acknowledging that pain and sleep fragmentation potentiate autonomic arousal and hot flashes.

This collaborative model helps you get a care plan that addresses your symptoms from every angle, leading to better, more sustainable outcomes.

Defining Menopause and the Timeline of Vasomotor Symptoms

The journey through menopause is unique for every woman. As a clinician, I frequently encounter patients in the perimenopausal and menopausal stages who feel overwhelmed. A common question I hear is, “Am I going to deal with these hot flashes for the rest of my life, or is there something I can do?” Yes, there is a lot we can do. This question opens the door to a crucial conversation about the many available treatment options.

Key definitions I share with patients:

• Menopause: The final menstrual period (FMP) followed by 12 consecutive months without menstruation, reflecting the loss of ovarian follicular function (Harlow & Paramsothy, 2011).
• Early vs. late transition: Cycle variability (±7 days) heralds early transition; gaps? 60 days indicate late transition; postmenopause begins after the FMP, with early postmenopause spanning the first 1–6 years, when VMS is usually most intense (Harlow & Paramsothy, 2011; Santoro & Randolph, 2011).

Clinical observation from practice: Many patients, like Jenny, notice perimenopausal sleep disruption and night sweats 1–2 years before the FMP, with symptoms peaking in the first years after the FMP and tapering later. However, up to 50% may experience VMS for more than 7 years, with notable ethnic and individual variability (Avis et al., 2015).

Physiology: Why Hot Flashes and Menopause Symptoms Happen

I explain vasomotor physiology in plain language and then connect it to targeted interventions. Menopause is defined by the loss of ovarian follicular function and declining estradiol/estrone production, ultimately leading to amenorrhea. The drop in estrogen impacts multiple systems:

• The HPO axis and estrogen decline:

• • Diminishing ovarian follicles reduce inhibin, which normally restrains pituitary FSH. When inhibin falls, FSH rises; estradiol (E2) production becomes erratic and generally declines over time (Burger et al., 2007).
  • After menopause, estrone (E1), derived from adrenal precursors and adipose aromatization, becomes the predominant estrogen but is much weaker than estradiol (Santoro & Randolph, 2011).

• Thermoregulatory control and the narrowed thermoneutral zone:

• • The hypothalamus maintains core temperature within a thermoneutral zone, dampening responses to minor fluctuations.
  • With estrogen withdrawal, this zone narrows. Small increases in core temperature now trigger a heat-dissipation response—peripheral vasodilation and sweating—that is experienced as a hot flash (Freedman, 2001; Rance et al., 2013).

• KNDy neurons and neurokinin B signaling:

• • KNDy (kisspeptin/neurokinin B/dynorphin) neurons in the hypothalamic arcuate nucleus regulate both GnRH/LH pulsatility and thermoregulation. Estrogen typically restrains NKB-driven excitation of KNDy neurons.
  • With lower estrogen, NKB effects become unopposed, increasing neuronal activity, altering LH pulsatility, and contributing to hot flashes (Rance et al., 2013; Prague et al., 2017).
  • Clinical translation: Antagonizing NKB signaling (e.g., with NK3 receptor antagonists) reduces hot flashes—proof of mechanism (Prague et al., 2017).

• Genitourinary tract:

• • Reduced estrogen thins the vaginal epithelium, lowers glycogen content, shifts the microbiome away from lactobacilli, increases vaginal pH, and reduces mucosal immunity. The result is genitourinary syndrome of menopause (GSM), characterized by dryness, dyspareunia, recurrent UTIs, and urethral irritation (The NAMS 2023 Position Statement, 2023).

• Bone metabolism:

• • Estrogen deficiency increases osteoclast activity and bone resorption, accelerating bone loss and risk of osteopenia and osteoporosis (Cosman et al., 2014).

• Risk and variability:

• • Severe, prolonged VMS is associated with higher cardiovascular risk markers, including endothelial dysfunction and subclinical atherosclerosis in some cohorts (Thurston et al., 2017). While causality is complex, this association informs our emphasis on cardiometabolic screening and lifestyle interventions.

Diagnosing VMS Without Over-Testing

For women in the typical age range (45–55) with a clear symptom pattern and menstrual history, diagnosis is clinical. I avoid routine hormone panels in average-risk cases because:

• FSH, estradiol, and other hormones fluctuate widely in perimenopause, limiting single-test reliability (Santoro & Randolph, 2011).
• Results rarely change management when the clinical picture is typical. Exceptions include suspected premature ovarian insufficiency, atypical presentations, or situations where confirming ovarian status could change therapeutic choices. Shared decision-making guides testing.

History and exam priorities I use:

• Menstrual patterns: cycle variability, skipped cycles, amenorrhea> 12 months.
• Symptom inventory: frequency/severity of hot flashes, sleep impact, mood, urogenital symptoms, cognition, joint pain.
• Risk assessment: family and personal history of breast cancer, VTE, stroke, CVD, migraines with aura, liver disease, uncontrolled hypertension, or smoking.
• Comorbidities: thyroid disease, anemia, infections, medication effects (e.g., SSRIs, SNRIs, tamoxifen) that can mimic or modify VMS.
• Physical exam: vitals, BMI/waist circumference, blood pressure, signs of vulvovaginal atrophy, thyroid exam, musculoskeletal assessment for pain drivers.

Understanding Your Options for Menopausal Symptom Relief

We start with a thorough discussion, exploring options from lifestyle changes to advanced medical therapies. The goal is always to find what works best for you.

• Lifestyle & Home Management: We always start here. Simple changes in diet, exercise, and stress management can have a profound impact on symptom severity.
• Hormonal Preparations (Hormone Therapy): Often considered the most effective approach for moderate to severe symptoms when no contraindications exist. These can be categorized into estrogen-only preparations and estrogen-progestin combination therapies.
• Non-Hormonal Medications: For individuals who cannot or prefer not to use hormones, options like certain antidepressants (e.g., Paroxetine) and newer classes of drugs (e.g., NK3R antagonists) can be very effective.
• Non-Pharmacological & Mind-Body Therapies: Techniques like Cognitive Behavioral Therapy (CBT) and clinical hypnosis are emerging as powerful, low-risk tools. Research shows that CBT can significantly reduce the severity of hot flashes, though not necessarily their frequency (Mann et al., 2012). The primary challenges with these therapies are often access to qualified providers and insurance coverage.

---

Aligned & Empowered: Chiropractic Conversations on Women’s Health- Video

---

A Deeper Dive into Hormone Therapy

When we start discussing hormone therapy, I know it can bring up a lot of questions and concerns, largely stemming from past studies like the Women’s Health Initiative (WHI). It’s my job to help you navigate this information with clarity and confidence. The U.S. Food and Drug Administration (FDA) has approved hormone therapy for several specific indications in perimenopausal and menopausal women:

1. Treatment of Moderate to Severe Vasomotor Symptoms (VMS): This is the most common reason for prescribing hormone therapy, referring to the hot flashes and night sweats that can disrupt daily life and sleep.
2. Prevention of Bone Loss: Estrogen is crucial for maintaining bone density. Hormone therapy can be a vital tool in preventing osteoporosis.
3. Premature Estrogen Loss: For women who experience premature or early menopause (before age 40 or 45), hormone therapy helps replace the estrogen their bodies would naturally produce, protecting their long-term bone, cardiovascular, and cognitive health.
4. Genitourinary Syndrome of Menopause (GSM): This includes symptoms like vaginal dryness, pain with intercourse, and urinary urgency. If GSM is the only symptom, we typically prefer local estrogen therapy (creams, rings, tablets) applied directly to the vaginal area. However, if a woman suffers from both VMS and GSM, systemic hormone therapy can effectively treat both conditions simultaneously.

The Guiding Principle of Hormone Therapy Individualization

While organizations like The North American Menopause Society provide excellent guidelines, it’s critical to remember that these are generalized recommendations. The most effective and safest approach to hormone therapy is one that is highly individualized. Your treatment plan should be a product of shared decision-making between you and your healthcare team, tailored to your specific symptoms, health profile, and personal preferences.

The concern I hear most often from patients is about the risk of breast cancer. This is a valid and important topic. A detailed personal and family health history is the first step. We need to know: Have you ever had breast cancer? Is there a strong family history? Are there known genetic mutations like BRCA1 or BRCA2? All these factors help us assess your individual risk profile.

Exploring Transdermal Hormone Therapies: A Safer First Step

In our practice, we often consider transdermal hormone therapy as the first-line option for many patients. This includes patches, gels, and mists. The primary advantage of this delivery method is that it allows estrogen to be absorbed directly into the bloodstream.

Why Is This So Important?

When you take an oral estrogen pill, it must first pass through your digestive system and then undergo “first-pass metabolism” in the liver. This process alters the estrogen molecule and increases the production of clotting factors. This is why oral estrogens are associated with a higher risk of blood clots (deep vein thrombosis or DVT) and stroke compared to their transdermal counterparts (Canonico et al., 2007). By bypassing the liver, transdermal estrogen significantly mitigates this risk, making it a safer choice for many women, particularly those with risk factors for VTE.

We have numerous transdermal options available, and we always aim to start with the lowest effective dose to manage your symptoms and titrate up only if necessary.

• Estradiol Patches: These are a popular choice. They come in generic and brand-name versions (such as Vivelle-Dot and Climara) and are typically replaced once or twice a week. Doses range from 0.025 mg/day to 0.1 mg/day. We can start you on a low dose and see how your symptoms respond before considering an increase.
• Estradiol Mists and Gels: Products such as EvaMist (a spray) or Estrace Gel (a pump gel) are applied daily to the skin, usually on the forearm or inner thigh. They offer metered dosing, which allows for precise and consistent application. A key piece of advice I always give my patients is to let the product dry completely before getting dressed to ensure full absorption.
• Combination Patches: For women who still have their uterus, we need to add a progestin to protect the uterine lining. Combination patches that contain both estradiol and a progestin are available. In my clinical experience, some patients may experience irregular spotting with these patches, but many others find them convenient and effective.

Oral and Other Hormone Therapy Options

While transdermal is often preferred, oral hormone therapy remains a valid and effective option for many. It is essential to understand the different types and their specific use cases.

Estrogen-Only Oral Therapy

This option is reserved exclusively for women who have had a hysterectomy (do not have a uterus). Without a uterus, there is no risk of estrogen causing the uterine lining (endometrium) to thicken, which could otherwise increase the risk of endometrial cancer.

• Types of Oral Estrogen: There is a wide variety available, including:

• • Conjugated Equine Estrogens (CEE): Derived from pregnant mares’ urine (e.g., Premarin). This is one of the oldest and most-studied forms.
  • Plant-Derived & Synthetic Estrogens: These are chemically identical to the estrogen your body makes (bioidentical).

I’ve had patients express a preference for non-animal-derived products, and that’s a perfect example of shared decision-making. We can easily choose a plant-based or synthetic option that aligns with your values.

Estrogen + Progestin Oral Therapy

If you have a uterus, you must take a progestin along with your estrogen. Progestin’s job is to protect the endometrium. It causes the lining to shed regularly (or keeps it thin), preventing the buildup of cells that could lead to cancer.

• Combination Pills: Many products combine estrogen and a progestin in one pill (e.g., Prempro).
• Synthetic Progestins: Just like with birth control pills, there are many different types of synthetic progestins (e.g., medroxyprogesterone acetate, drospirenone, norethindrone acetate). Sometimes, a patient might experience side effects like mood changes or depression on one type of progestin. In these cases, we can switch to a different formulation to find one that works best for their body.
• Micronized Progesterone: This is a bioidentical form of progesterone (e.g., Prometrium). It is often preferred because it has a more favorable profile regarding breast cancer risk and cardiovascular effects compared to some synthetic progestins (Fournier et al., 2008). It also has a calming effect via GABA-A modulatory effects and can aid sleep, making it a great option to take at bedtime.

Specialized and Parenteral Hormone Therapies

For more specific situations or severe symptoms, we have other advanced options.

SERMs: A Unique Class of Medication

Selective Estrogen Receptor Modulators (SERMs) are fascinating drugs. A combination product containing conjugated estrogen and a SERM called bazedoxifene is available. This combination offers a unique profile:

• It acts like estrogen on the bones, helping to protect against osteoporosis.
• It acts like an anti-estrogen on the uterine lining, providing endometrial protection without the need for a separate progestin. This means no uterine bleeding.
• It also effectively reduces vasomotor symptoms and can decrease breast density.

Parenteral (Injectable) Estrogen

Injectable estrogen is generally reserved for individuals with severe menopausal symptoms that haven’t responded to other therapies. These are intramuscular injections that provide a higher, more potent dose of estrogen. There are different formulations, like estradiol valerate and estradiol cypionate. The main difference is in their absorption and peak levels. Estradiol valerate tends to peak faster, while cypionate has a slower rise and fall, which some patients find provides a more stable feeling. Ultimately, the long-term therapeutic effect is similar, so the choice often comes down to provider and patient preference.

How We Individualize Treatment Stepwise, Evidence-Based, and Integrative

Our team crafts a plan based on symptom severity, health risks, patient preferences, and functional goals. Here is how I build the logic:

1) Lifestyle Foundation and Sleep Restoration

Why: Even modest improvements in sleep, physical activity, and stress buffering reduce sympathetic surges and may narrow the perceived intensity of hot flashes. Exercise improves vascular tone, endothelial function, insulin sensitivity, and sleep architecture.

What we do:

• Sleep: Cognitive-behavioral therapy for insomnia (CBT-I) principles, regular sleep-wake timing, cool/dark bedroom, breathable bedding, and pre-sleep wind-down rituals.
• Temperature strategies: layered clothing, a bedside fan, moisture-wicking sheets, and avoiding late alcohol/spicy meals.
• Exercise: Combined aerobic and resistance training 3–5 days/week; add mobility and core work to support spinal mechanics and breathing efficiency.
• Mind-body: Diaphragmatic breathing, HRV biofeedback, mindfulness to reduce arousal thresholds that can precipitate or amplify episodes.

2) The Role of Integrative Chiropractic Care in Menopausal Health

You might wonder how chiropractic care fits into a discussion about menopause and hormones. The connection is more direct than you might think. Symptoms are not just hormones; they’re systems. My clinical experience in personal injury and integrative medicine has shown that addressing the biomechanical, autonomic, and inflammatory milieu can amplify the benefits of MHT or, for women who avoid hormones, provide meaningful relief (Jimenez, n.d.-a; Jimenez, n.d.-b).

• Musculoskeletal Health and Pain Management: The decline in estrogen directly impacts your musculoskeletal system, contributing to bone density loss (osteoporosis) and affecting the integrity of your cartilage, ligaments, and tendons. This can lead to increased joint pain, stiffness, headaches, and a higher risk of injury. Chiropractic adjustments and spinal mobilization help maintain proper joint function, improve mobility, and reduce pain. By ensuring your spine and joints are properly aligned, we can alleviate undue stress on your body as it adapts to these hormonal shifts.
• Nervous System and Autonomic Regulation: The autonomic nervous system plays a key role in regulating body temperature (hot flashes), sleep, and mood. Chiropractic care is centered on optimizing the function of the nervous system. Cervical and thoracic segmental dysfunctions can contribute to sympathetic overactivity. Carefully applied spinal manipulation and mobilization may normalize afferent input and improve autonomic balance, potentially aiding sleep, tension headaches, and perceived hot flash intensity.
• Posture, Respiration, and Sleep: Thoracic mobility and diaphragmatic breathing techniques enhance vagal tone and reduce nocturnal arousals. We utilize myofascial release of scalene, SCM, and upper trapezius muscles to relieve tension and improve chest wall expansion. Improved posture and rib mechanics support respiratory efficiency, lowering sympathetic drive that can worsen night sweats.

3) Functional Medicine Synergy: Nutrition, Metabolism, and Microbiome

Why: Hot flashes are linked with adiposity, insulin resistance, and inflammation; nutrition and targeted supplementation can support estrogen metabolism, vasodilation, and sleep (Huang et al., 2022).

What we do:

• Nutritional pattern: Mediterranean-style diet emphasizing vegetables, legumes, omega-3-rich fish, nuts/seeds, and high-fiber whole foods to improve endothelial function and glycemic control.
• Supplements (when appropriate):

• • Omega-3 fatty acids for inflammation and endothelial health.
  • Magnesium glycinate for sleep quality and muscle relaxation.
  • Vitamin D for bone health and immune modulation.

• Metabolic screening: Fasting glucose, lipid profile, waist circumference; we integrate cardiometabolic coaching when risk markers are elevated.

4) Medical Therapy: Hormonal and Non-hormonal Options with Oversight

Dr. Cardenas oversees medical prescribing, risk stratification, and follow-up safety.

Hormone therapy (HT):

• Why: Systemic estrogen therapy is the most effective treatment for moderate-to-severe VMS in healthy, recently menopausal women (NAMS, 2023).
• How we use it: Individualized dosing, often starting with transdermal estradiol for lower VTE risk. We add micronized progesterone to protect the endometrium in women with a uterus.
• Who benefits most: Women within 10 years of the FMP, under age ~60, without contraindications.

Non-hormonal pharmacologic options:

• Why: For women who cannot or choose not to use HT, several classes reduce hot flashes via central thermoregulatory modulation.
• Options we discuss: SSRIs/SNRIs (Paroxetine, venlafaxine), gabapentin or pregabalin, clonidine, and NK3 receptor antagonists.

Patient Story Bringing It All Together for Jenny

When I met Jenny, 52, she had 15 months of amenorrhea and disabling night sweats worsening over two years. We reviewed the menopausal timeline and physiology: declining estradiol, increased FSH variability, KNDy neuron overactivity, and a narrowed thermoneutral zone.

Our plan:

• Lifestyle Changes: She began with sleep and temperature hygiene, daily diaphragmatic breathing, and a cooling pillow and sheets. We reduced evening alcohol intake and recommended earlier, lighter dinners.
• Integrative Chiropractic Care: We addressed a stiff cervicothoracic junction and chronic desk-related posture. With gentle adjustments, soft-tissue work on the scalenes and upper trapezius, and rib mobility drills, she reported fewer nocturnal awakenings from neck discomfort within 3–4 weeks—consistent with our clinic observations that reducing mechanical nociception calms autonomic reactivity.
• Functional Medicine & Nutrition: Her exercise shifted to a 4-day split of resistance and aerobic sessions. Her nutrition moved to a Mediterranean pattern, adding omega-3s and magnesium glycinate at night.
• Medical Therapy: After shared decision-making with Dr. Cardenas, given her low cardiovascular and cancer risk, we initiated low-dose transdermal estradiol with micronized progesterone.

Within 4 weeks, her night sweats decreased in frequency and intensity; by 8–12 weeks, she reported consistent uninterrupted sleep 5–6 nights per week. We continued monitoring blood pressure and lipid profile, maintained exercise and chiropractic sessions at a lower frequency, and set a 12–18 month horizon to reassess HT need.

Navigating Comorbidities and Contraindications

Not all contraindications are absolute. This is where careful internal medicine oversight and chiropractic-functional coordination shine.

• Relative or situational considerations:

• • History of VTE, established cardiovascular disease, hyperlipidemia, diabetes, migraines with aura: We avoid oral estrogens and favor transdermal estradiol if benefits outweigh risks. We coordinate with neurology, cardiology, and primary care.
  • Age and timing: Best outcomes typically occur when MHT is initiated before age 60 and within 10 years of the onset of menopause.

• Situations requiring pause or extra evaluation:

• • Undiagnosed postmenopausal bleeding: Stop systemic hormones, assess with transvaginal ultrasound, and consider endometrial biopsy.
  • Untreated hypertension: Treat and control before initiating therapy.
  • Active liver disease or abnormal liver function: Avoid oral conjugated estrogens.

• Estrogen-sensitive cancers:

• • In current or past breast cancer, we collaborate with the oncologist. Low-dose vaginal estrogen may be acceptable for refractory GSM in selected cases after oncology approval.

Follow-Up and Long-Term Management

Hormone therapy is not a “set it and forget it” treatment. It requires ongoing monitoring and partnership between you and your healthcare team.

• Dose Adjustments: Our initial goal is to find the right product and dose that provides symptom relief with minimal side effects.
• Regular Follow-Ups: Your follow-up schedule will depend on your overall health status. If you have comorbidities like hypertension or a history of migraines, we will want to see you more frequently. Initial follow-up is at 6 weeks, with subsequent visits at 3–6-month intervals, then annually once stable.
• Open Communication: The most important part is open communication. I encourage my patients to let me know what is and isn’t working so we can fine-tune your regimen.

The journey through menopause is unique for every woman. At Injury Medical Clinic PA, we provide a supportive, evidence-based, and integrative framework to help you navigate this transition with health and vitality. By combining the best of internal medicine, functional medicine, and chiropractic care, we can create a truly personalized plan that honors your individual needs and empowers you to thrive.

Clinical Observations and Resources

From my work in El Paso and shared case narratives, I have observed consistent improvement in VMS distress when autonomic regulation, sleep, and musculoskeletal contributors are addressed alongside hormonal or non-hormonal therapy. For more on our clinical approach and outcomes, explore:

• Personal Injury Doctor Group: https://personalinjurydoctorgroup.com/
• Professional profile and additional commentary: https://www.linkedin.com/in/dralexjimenez/

References

• Avis, N. E., Crawford, S. L., & Greendale, G. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175(4), 531–539.
• Burger, H. G., Hale, G. E., Robertson, D. M., & Dennerstein, L. (2007). A review of hormonal changes during the menopausal transition: Focus on findings from the Melbourne Women’s Midlife Health Project. Human Reproduction Update, 13(6), 559–565.
• Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M. T., Wahl, D., Emmerich, J., Scarabin, P. Y., & ESTHER Study Group. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845.
• Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014). Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis International, 25(10), 2359–2381.
• Fournier, A., Berrino, F., & Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103–111.
• Freedman, R. R. (2001). Physiology of hot flashes. American Journal of Human Biology, 13(4), 453–464.
• Harlow, S. D., & Paramsothy, P. (2011). Menstruation and the menopausal transition. Obstetrics and Gynecology Clinics of North America, 38(4), 595–607.
• Huang, T., Yang, B., & Zheng, J. (2022). Dietary patterns and vasomotor symptoms: A review. Menopause, 29(6), 706–716.
• Jimenez, A. (n.d.-a). Personal Injury Doctor Group.
• Jimenez, A. (n.d.-b). LinkedIn: Dr. Alex Jimenez.
• L’Hermite, M. (2017). Bioidentical menopausal hormone therapy: registered hormones (non-compounded) are optimal. Climacteric, 20(4), 331–338.
• Mann, E., Smith, M. J., Hellier, J., Balabanovic, J. A., Hamed, H., Grunfeld, E. A., & Hunter, M. S. (2012). Cognitive behavioral treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomized controlled trial. The Lancet. Oncology, 13(3), 309–318.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., Wactawski-Wende, J., Jackson, R. D., Limacher, M., Gass, M. L., Ockene, J. K., Gaba, C., OO’Sullivan M. J., Kaunitz, A. M., Hsia, J., … Wallace, R. B. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368.
• Mauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017). Menopausal hormone therapy and type 2 diabetes prevention. Diabetes Care, 40(1), 44–53.
• Nelson, H. D., Vesco, K. K., Haney, E., et al. (2006). Non-hormonal therapies for menopausal hot flashes: Systematic review and meta-analysis. JAMA, 295(17), 2057–2071.
• North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573–590.
• Prague, J. K., Roberts, R. E., Comninos, A. N., et al. (2017). Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: Evidence from a phase 2 trial. The Lancet, 389(10081), 1809–1820.
• Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A., & Krajewski-Hall, S. J. (2013). Modulation of body temperature and LH secretion by hypothalamic KNDy neurons. Endocrinology, 154(3), 1194–1205.
• Santoro, N., & Randolph, J. F. (2011). Reproductive hormones and the menopause transition. Obstetrics and Gynecology Clinics of North America, 38(3), 455–466.
• Thurston, R. C., Chang, Y., Barinas-Mitchell, E., Jennings, J. R., von Känel, R., Landsittel, D. P., & Santoro, N. (2017). Vasomotor symptoms and subclinical cardiovascular disease in the Study of Women’s Health Across the Nation. Stroke, 48(3), 840–846.

SEO Tags: Menopause, Hormone Therapy, Perimenopause, Hot Flashes, vasomotor symptoms, night sweats, KNDy neurons, neurokinin B, estrogen therapy, transdermal estradiol, non-hormonal therapy, NK3 receptor antagonists, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, Integrative Medicine, Chiropractic Care, El Paso TX, Functional Medicine, Oral Hormone Therapy, SERMs, Genitourinary Syndrome of Menopause, Women’s Health, Estrogen, Progesterone, Individualized Healthcare, Multidisciplinary Clinic, Personal Injury Doctor, micronized progesterone, vaginal estrogen, overactive bladder, sleep, osteoporosis, bone health, cardiovascular risk, diabetes risk, pelvic floor therapy, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic